Effects of Tolcapone on Decision Making and Alcohol Intake in Alcohol Users
Effects of Tolcapone on Decision Making and Alcohol Intake Using a Laboratory Bar in Moderate to Heavy Social Drinkers
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Berkeley, California, United States, 94704
- University of California, Berkeley
-
San Francisco, California, United States, 94109
- University of California, San Francisco
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy volunteers who are 21-40 years of age
- If female, 10 or more alcoholic drinks must be consumed weekly.
- If male, 14 or more alcoholic drinks must be consumed weekly.
- Meets DSM-V criteria for Alcohol Use Disorder (AUD).
- If female, must be non-lactating, not pregnant, and using a reliable contraception method (i.e. abstinence, intrauterine device [IUD], hormonal birth control, or barrier method).
- Ability to read and speak English.
- High school graduate.
- Able and willing to provide an informed consent.
- Able to understand and follow the instructions of the investigator, including the delayed discounting tasks. Residing within 5 miles of the study site.
Exclusion Criteria:
- Positive urine drug screen (except marijuana).
- Using cocaine, stimulants (other than nicotine and caffeine), amphetamines, hallucinogens, ecstasy, opiates, sedatives, pain pills, sleeping pills. or other psychoactive drugs within 2 weeks of the start of the study (except marijuana).
- Marijuana use more than 3 times/week.
- Current enrollment in an alcohol, or other drug treatment program or current legal problems relating to alcohol, or other drug use.
- Currently trying to quit alcohol use.
- History of major alcohol related complications within the preceding 2 years (liver failure/cirrhosis, pancreatitis, esophageal varices, etc.).
- Two SGPT/ALT or SGOT/AST values greater than the upper limit of normal.
- Unable to pass the Standard Field Sobriety Test in a sober state (BAC = 0.00).
- BAC level >0.05% at the beginning of screening visit (within margin of error of detection).
- Regular use of any of the drugs on the tolcapone contraindications list OR within 2 weeks of drug administration.
- Severe low blood (< 90/50) pressure or uncontrolled high blood pressure (>160/100). Allergy or intolerance to tolcapone.
- Subject has received an investigational drug within 30 days of the screening visit.
- Subject is considered unsuitable for the study in the opinion of the investigator or clinician for any other reason (such as an Axis II personality disorder that makes the subject unable to comply with study instructions, per the Clinician's judgement.)
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Tolcapone First, then Placebo
Tolcapone arm first: 5 days of 100 mg tolcapone TID, followed by washout period, then 5 days of placebo TID
|
Other Names:
|
|
Placebo Comparator: Placebo First, then Tolcapone
Placebo arm first: 5 days placebo, followed by washout period, followed by 5 days of 100 mg tolcapone TID
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Drinks Consumed in a Laboratory Bar Session
Time Frame: A laboratory bar session is 1 hour long
|
Number of drinks consumed in a laboratory bar session (out of a maximum of 4 drinks available) following either placebo or tolcapone administration.
|
A laboratory bar session is 1 hour long
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Jennifer Mitchell, PhD, University of California, San Francisco
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Drinking Behavior
- Alcohol-Related Disorders
- Substance-Related Disorders
- Alcohol Drinking
- Alcoholism
- Impulsive Behavior
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antiparkinson Agents
- Anti-Dyskinesia Agents
- Catechol O-Methyltransferase Inhibitors
- Tolcapone
Other Study ID Numbers
Other Study ID Numbers
- Tolcapone Lab Bar
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.